Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The German method for setting ceiling prices for drugs: in some cases less data are required.

Gandjour A, Gafni A.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):403-9. doi: 10.1586/erp.11.45.

PMID:
21831020
2.

Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules.

Gandjour A.

Appl Health Econ Health Policy. 2011 Mar 1;9(2):65-71. doi: 10.2165/11586640-000000000-00000.

PMID:
21332250
3.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
4.

[Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].

Führlinger S.

Wien Med Wochenschr. 2006 Dec;156(23-24):612-8. German.

PMID:
17211765
5.

[Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].

Hoomans T, van der Roer N, Severens JL, Delwel GO.

Ned Tijdschr Geneeskd. 2010;154:A958. Dutch.

PMID:
20699045
6.

[Procedures and methods of benefit assessments for medicines in Germany].

Bekkering GE, Kleijnen J.

Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25. German.

PMID:
19034813
7.

Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests.

Cleemput I, van Wilder P, Huybrechts M, Vrijens F.

Value Health. 2009 Jun;12(4):441-9. doi: 10.1111/j.1524-4733.2008.00469.x. Epub 2008 Nov 11.

8.

[Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].

Krauth C, John J, Aidelsburger P, Brüggenjürgen B, Hansmeier T, Hessel F, Kohlmann T, Moock J, Rothgang H, Schweikert B, Seitz R, Wasem J; AG Methoden der gesundheitsökonomischen Evaluation.

Gesundheitswesen. 2008 Jun;70(6):e1-16. doi: 10.1055/s-2008-1077059. German.

PMID:
18661452
9.

[Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Z Rheumatol. 2004 Feb;63(1):59-75. German.

PMID:
14991279
10.
11.

Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor.

Gandjour A, Gafni A, Schlander M.

Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):123-9. doi: 10.1586/14737167.2014.868313. Epub 2013 Dec 20.

PMID:
24354766
12.

Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.

Hoomans T, Severens JL, van der Roer N, Delwel GO.

Pharmacoeconomics. 2012 Mar;30(3):219-27. doi: 10.2165/11539850-000000000-00000.

PMID:
22074610
13.

[Cost-effectiveness evaluation of drugs: multidisciplinary collaboration and transparency are key].

Mueller EA, Kirch W.

Med Klin (Munich). 2008 Oct 15;103(10):712-6. doi: 10.1007/s00063-008-1111-2. Epub 2008 Oct 21. German.

PMID:
18936896
14.

Economic evaluation for pharmaceuticals in Germany.

Jönsson B.

Eur J Health Econ. 2007 Sep;8 Suppl 1:S1-2. No abstract available.

PMID:
17638033
15.

Methods for determining cost-benefit ratios for pharmaceuticals in Germany.

von der Schulenburg J, Vauth C, Mittendorf T, Greiner W.

Eur J Health Econ. 2007 Sep;8 Suppl 1:S5-31. Review.

PMID:
17582539
16.

[Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].

Delwel GO, Sprenger MJ.

Ned Tijdschr Geneeskd. 2002 Jun 8;146(23):1068-71. Dutch.

PMID:
12085554
17.
18.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171
19.

[Decision-analytical modelling of costs per QALY in the context of the German Social Law].

Rogowski WH, Landauer M, John J.

Gesundheitswesen. 2009 Nov;71(11):739-50. doi: 10.1055/s-0029-1220756. Epub 2009 Jun 23. Review. German.

PMID:
19551622
20.

[Cost-benefit analysis of an evidence-based secondary prevention of coronary heart diseases by statins. An analysis for Germany from a social security perspective].

Klever-Deichert G, Hinzpeter B, Wendland G, Lauterbach K.

Med Klin (Munich). 2000 Jun 15;95(6):305-13. German.

PMID:
10935414

Supplemental Content

Support Center